Guadecitabine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Guadecitabine
Accession Number
DB11918
Type
Small Molecule
Groups
Investigational
Description

Guadecitabine is under investigation for the treatment of Previously Treated Metastatic Colorectal Cancer.

Structure
Thumb
Synonyms
Not Available
External IDs
SGI-110
Product Ingredients
IngredientUNIICASInChI Key
Guadecitabine Sodium0RB89YH367929904-85-8XLHBNJPXFOZFNJ-BYKQGDNKSA-M
Categories
UNII
2KT4YN1DP7
CAS number
929901-49-5
Weight
Average: 557.417
Monoisotopic: 557.138375007
Chemical Formula
C18H24N9O10P
InChI Key
GUWXKKAWLCENJA-WGWHJZDNSA-N
InChI
InChI=1S/C18H24N9O10P/c19-16-22-6-27(18(31)25-16)12-2-8(9(3-28)35-12)37-38(32,33)34-4-10-7(29)1-11(36-10)26-5-21-13-14(26)23-17(20)24-15(13)30/h5-12,28-29H,1-4H2,(H,32,33)(H2,19,25,31)(H3,20,23,24,30)/t7-,8-,9+,10+,11+,12+/m0/s1
IUPAC Name
{[(2R,3S,5R)-5-(4-amino-2-oxo-1,2-dihydro-1,3,5-triazin-1-yl)-2-(hydroxymethyl)oxolan-3-yl]oxy}({[(2R,3S,5R)-5-(2-amino-6-oxo-6,9-dihydro-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy})phosphinic acid
SMILES
NC1=NC(=O)C2=C(N1)N(C=N2)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)O[C@H]2C[C@@H](O[C@@H]2CO)N2C=NC(N)=NC2=O)O1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Guadecitabine.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Guadecitabine.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Guadecitabine.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Guadecitabine.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
71587872
PubChem Substance
347828249
ChemSpider
32701891
ChEMBL
CHEMBL3544916

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)2
1Active Not RecruitingTreatmentMetastatic Colorectal Cancer (MCRC)1
1CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
1RecruitingHealth Services ResearchCastration-Resistant Prostatic Cancer / Lung Cancer Non-Small Cell Cancer (NSCLC)1
1RecruitingTreatmentExtrahepatic Bile Duct Adenocarcinoma, Biliary Type / Gallbladder Adenocarcinoma, Biliary Type / Pancreatic Adenocarcinoma Metastatic / Recurrent Cholangiocarcinoma / Recurrent Gallbladder Carcinoma / Recurrent Hepatocellular Carcinoma / Recurrent Intrahepatic Cholangiocarcinoma / Recurrent Pancreatic Carcinoma / Stage III Gallbladder Cancer AJCC V7 / Stage III Hepatocellular Carcinoma AJCC v7 / Stage III Intrahepatic Cholangiocarcinoma AJCC v7 / Stage III Pancreatic Cancer AJCC v6 and v7 / Stage IIIA Gallbladder Cancer AJCC v7 / Stage IIIA Hepatocellular Carcinoma AJCC v7 / Stage IIIB Gallbladder Cancer AJCC v7 / Stage IIIB Hepatocellular Carcinoma AJCC v7 / Stage IIIC Hepatocellular Carcinoma AJCC v7 / Stage IV Gallbladder Cancer AJCC v7 / Stage IV Hepatocellular Carcinoma AJCC v7 / Stage IV Pancreatic Cancer AJCC v6 and v7 / Stage IVA Gallbladder Cancer AJCC v7 / Stage IVA Hepatocellular Carcinoma AJCC v7 / Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7 / Stage IVB Gallbladder Cancer AJCC v7 / Stage IVB Hepatocellular Carcinoma AJCC v7 / Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7 / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Carcinoma1
1RecruitingTreatmentGerm Cell Tumors / Testicular Cancer / Testis cancer1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentMetastatic Melanoma1
1, 2CompletedOtherCMML / Leukemia Acute Myeloid Leukemia (AML) / Smith-Magenis Syndrome1
1, 2Not Yet RecruitingTreatmentColorectal Adenocarcinoma / CpG Island Methylator Phenotype / Metastatic Microsatellite Stable Colorectal Carcinoma / Refractory Colorectal Carcinoma / Stage IV Colorectal Cancer AJCC v8 / Stage IVA Colorectal Cancer AJCC v8 / Stage IVB Colorectal Cancer AJCC v8 / Stage IVC Colorectal Cancer AJCC v81
1, 2RecruitingTreatmentAdvanced Kidney Cancer / Clear Cell Renal Cell Carcinoma / Renal Cancers1
1, 2RecruitingTreatmentChronic Myelomonocytic Leukemia / Myelodysplastic Syndrome / Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes1
1, 2SuspendedTreatmentPlatinum-Resistant Fallopian Tube Carcinoma / Platinum-Resistant Ovarian Carcinoma / Platinum-Resistant Primary Peritoneal Carcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2Active Not RecruitingTreatmentHigh Risk Myelodysplastic Syndrome / Leukemias1
2Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myeloid Dysplastic Syndrome1
2Active Not RecruitingTreatmentLeukemias / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentPreviously Treated Metastatic Colorectal Cancer1
2CompletedTreatmentHepatocellular,Carcinoma1
2CompletedTreatmentOvarian Cancer1
2CompletedTreatmentSmith-Magenis Syndrome1
2Not Yet RecruitingPreventionLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentExtensive-Stage Small Cell Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC)1
2RecruitingTreatmentGastrointestinal Stromal Tumors / Paraganglioma / Pheochromocytomas / Renal Cell Adenocarcinoma / Renal Neoplasms1
2RecruitingTreatmentAcute, recurrent Myeloid Leukemia / High Risk Acute Myeloid Leukemia / High Risk Myelodysplastic Syndrome / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Minimal Residual Disease / Myelodysplastic Syndrome / Myeloproliferative Disorders / Recurrent Myelodysplastic Syndrome1
2RecruitingTreatmentMyeloproliferative Neoplasms1
2RecruitingTreatmentRecurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma1
2RecruitingTreatmentTransitional Cell Carcinoma1
3Active Not RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentLeukemia, Myelomonocytic, Chronic / Myelodysplastic Syndromes1
3CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.89 mg/mLALOGPS
logP-2ALOGPS
logP-3.6ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)1.79ChemAxon
pKa (Strongest Basic)2.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count15ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area271.03 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity120.45 m3·mol-1ChemAxon
Polarizability49.74 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine 2'-deoxyribonucleoside monophosphates. These are purine nucleotides with monophosphate group linked to the ribose moiety lacking a hydroxyl group at position 2.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleotides
Sub Class
Purine deoxyribonucleotides
Direct Parent
Purine 2'-deoxyribonucleoside monophosphates
Alternative Parents
6-oxopurines / Hypoxanthines / Triazinones / Pyrimidones / Aminopyrimidines and derivatives / Aminotriazines / Dialkyl phosphates / 1,3,5-triazines / N-substituted imidazoles / Vinylogous amides
show 9 more
Substituents
Purine 2'-deoxyribonucleoside monophosphate / 6-oxopurine / Hypoxanthine / Imidazopyrimidine / Purine / Aminopyrimidine / Amino-1,3,5-triazine / Aminotriazine / Pyrimidone / Triazinone
show 28 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:00 / Updated on December 02, 2019 09:14